Fred Alger Management’s Apellis Pharmaceuticals APLS Stock Holding History

Fred Alger Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,949	Closed	-$112K	–	449
2023 Q3	$112K	Sell	2,949 -179,046	-98%	-$7.86M	﹤0.01%	417
2023 Q2	$16.6M	Sell	181,995 -249	-0.1%	-$21.5K	0.08%	169
2023 Q1	$12M	Sell	182,244 -24,019	-12%	-$1.39M	0.06%	186
2022 Q4	$10.7M	Buy	206,263 +71,961	+54%	+$3.82M	0.06%	208
2022 Q3	$9.17M	Sell	134,302 -2,197	-2%	-$130K	0.05%	212
2022 Q2	$6.17M	Buy	136,499 +67,716	+98%	+$3.09M	0.03%	244
2022 Q1	$3.5M	Buy	+68,783	New	+$3.04M	0.01%	302
2021 Q1	–	Sell	-14,811	Closed	-$847K	–	478
2020 Q4	$847K	Buy	+14,811	New	+$627K	﹤0.01%	382
2020 Q2	–	Sell	-5,000	Closed	-$134K	–	501
2020 Q1	$134K	Sell	5,000 -10,000	-67%	-$355K	﹤0.01%	404
2019 Q4	$459K	Sell	15,000 -16,000	-52%	-$443K	﹤0.01%	393
2019 Q3	$747K	Buy	31,000 +28,000	+933%	+$771K	﹤0.01%	353
2019 Q2	$76K	Buy	+3,000	New	+$61K	﹤0.01%	415

Other funds holding APLS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Fred Alger Management's APLS Position: Q4 2023 in Review

Fred Alger Management sold out of Apellis Pharmaceuticals (APLS) in Q4 2023, closing a stake of 2,949 shares — an estimated $112K sold.

Fred Alger Management first reported a position in APLS in Q2 2019 and held it in 12 quarters. The position peaked at $16.6M in Q2 2023. 283 funds tracked by Wall St. Rank hold APLS as of Q4 2023.

Fred Alger Management reported no remaining Apellis Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Fred Alger Management sold 2,949 Apellis Pharmaceuticals shares in Q4 2023, an estimated $112K.
Fred Alger Management first reported a position in Apellis Pharmaceuticals in Q2 2019 and held it in 12 quarters.
Fred Alger Management's Apellis Pharmaceuticals position peaked at $16.6M in Q2 2023.
283 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2023.

Based on Fred Alger Management's 13F filing for Q4 2023, filed 14 Feb 2024.